Results 111 to 120 of about 3,462,732 (382)

Selection of resistance to cisplatin in saccharomyces cerevisiae as a model for antineoplastic drugs studies [PDF]

, 2019
The budding yeast (S. cerevisiae) is an excellent eukaryotic model to study the antineoplastic drugs effects, due to the well-characterized metabolic and genetic characteristics and the conserved similarity in molecular mechanisms with other species ...
Burgos-Molina, Antonio Manuel, Gil-Carmona, Luisa, Lumbreras-Vega, Luis, Ruiz-Gomez, Miguel Jose   +3 more
core  

A pilot study of temsirolimus and body composition. [PDF]

, 2013
PurposeBody weight and composition play a role in cancer etiology, prognosis, and treatment response. Therefore, we analyzed the weight, body composition changes, and outcome in patients treated with temsirolimus, an mTor inhibitor that has weight loss ...
Janku, Filip, Kurzrock, Razelle, Naing, Aung, Parsons, Henrique A, Tsimberidou, Apostolia M, Veasey-Rodrigues, Heloisa, Wheler, Jennifer J   +6 more
core   +2 more sources

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source

Assessment of potential drug–drug interactions in an oncology unit of a tertiary care teaching hospital

Indian Journal of Medical and Paediatric Oncology, 2018
Context: Drug interactions are more common in cancer patients because they consume several medicines such as hormonal substances, anticancer drugs, and adjuvant drugs to treat comorbidities.
Ramya Kuzhikattu Vayalil, K Jayarama Shetty, Uday Venkat Mateti   +2 more
doaj   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Clotrimazole as a new frontier: Drug repurposing and its efficacy in cancer therapy

Cancer Pathogenesis and Therapy
Cancer, ranging from early stages to metastatic spread, is one of the leading causes of death globally. Current treatment options, including chemotherapy, radiotherapy, and targeted drugs, have limitations, such as significant side effects, drug ...
Shubham C. Karpe, Manjula Kiran, Sukhen Majhi, Jaipal Meena, Rajesh Kumar, Harish Chander, Anupkumar R. Anvikar, Harit Kasana   +7 more
doaj   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Ankaferd blood stopper: A novel hemostatic agent with unique antimicrobial, antineoplastic and regenerative properties [PDF]

, 2019
Aditi Chopra, Karthik Sivaraman
openalex   +1 more source

Mechanisms of cross resistance between cisplatin and bleomycin in saccharomyces cerevisiae [PDF]

, 2019
Tumor cells can simultaneously acquire resistance against a diverse group of drugs. This phenomenon is called pleotropic resistance or multidrug resistance.
Burgos-Molina, Antonio Manuel, Gil-Carmona, Luisa, Ruiz-Gomez, Miguel Jose   +2 more
core  

α-N-heterocyclic thiosemicarbazone derivatives as potential antitumor agents: A structure-activity relationships approach [PDF]

, 2009
α-N-Heterocyclic thiosemicarbazones, (N)-TSCs, are potent inhibitors of ribonucleotide reductase (RR). This enzyme plays a critical role in DNA synthesis and repair, and is a well-recognized target for cancer chemotherapeutic agents.
Matesanz, Ana I., Souza, Pilar
core   +2 more sources